AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Recombinant Plasma Protein Therapeutics Market - Industry Analysis, Size, Share, Growth, Trends & Forecast 2018-2026 - ResearchAndMarkets.com

November 25, 2019

DUBLIN--(BUSINESS WIRE)--Nov 25, 2019--

The “Recombinant Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026” report has been added to ResearchAndMarkets.com’s offering.

Global Recombinant Plasma Protein Therapeutics Market: Overview

This report analyzes the current and future scenario of the global recombinant plasma protein therapeutics market. Rise in focus on the treatment of rare diseases, increase in the number of cases with hemophilia A & hemophilia B, and surge in awareness about diagnosis and treatment of hemophilia and other bleeding disorders are major factors that are anticipated to drive the market during the forecast period. Moreover, increase in the number of healthcare providers prescribing recombinant plasma protein therapies for hemophilia A and rapid adoption of genetic engineering technologies in healthcare for the development of new therapeutics are also estimated to fuel the market during the forecast period.

The global recombinant plasma protein therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, cell line, indication, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global recombinant plasma protein therapeutics market.

New product launch and FDA approvals are also important factors that are expected to boost the market across the globe. For instance, in April 2018, Shire received FDA approval for VONVENDI recombinant von Willebrand factor indicated for perioperative management of bleeding in patients with von Willebrand disease (VWD)

Key Topics Covered:

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Recombinant Plasma Protein Therapeutics Market

4. Market Overview

4.1. Introduction

4.1.1. Product Definition

4.1.2. Industry Evolution/Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, 2016-2026

5. Key Insights

5.1. New Product Launch and Regulatory Approvals

5.2. Key Mergers & Acquisitions

5.3. Regulatory Scenario by Region/Country

6. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Key Findings/Developments

6.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

6.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Drug Class

7. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Cell Line

7.1. Introduction & Definition

7.2. Key Findings/Developments

7.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

7.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Cell Line

8. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Indication

8.1. Introduction & Definition

8.2. Key Findings/Developments

8.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

8.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Indication

9. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Region

9.3. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Region

10. North America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast

10.1. Introduction

10.2. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

10.3. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

10.4. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

10.5. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country, 2016-2026

10.6. North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis

11. Europe Recombinant Plasma Protein Therapeutics Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

11.3. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

11.4. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

11.5. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026

11.6. Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis

12. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis and Forecast

12.1. Introduction

12.2. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

12.3. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

12.4. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

12.5. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026

12.6. Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis

13. Latin America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast

13.1. Introduction

13.2. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

13.3. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

13.4. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

13.5. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026

13.6. Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis

14. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis and Forecast

14.1. Introduction

14.2. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016-2026

14.3. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016-2026

14.4. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016-2026

14.5. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016-2026

14.6. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis

15. Competitive Landscape

15.1. Market Player - Competition Matrix (By Tier and Size of companies)

15.2. Market Share Analysis By Company (2016)

15.3. Company Profiles

15.3.1. CSL Limited

15.3.2. Shire (Takeda Pharmaceutical Company Limited)

15.3.3. Octapharma

15.3.4. Novo Nordisk A/S

15.3.5. Bayer AG

15.3.6. Pfizer Inc.

15.3.7. Bioverativ Therapeutics, Inc. (Sanofi)

15.3.8. Aptevo Therapeutics

15.3.9. Pharming Group NV

For more information about this report visit https://www.researchandmarkets.com/r/4aj3c2

View source version on businesswire.com:https://www.businesswire.com/news/home/20191125005356/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/25/2019 05:57 AM/DISC: 11/25/2019 05:57 AM

http://www.businesswire.com/news/home/20191125005356/en